A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
200actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-01 | actual | When the study began enrolling |
| Primary completion | 2026-07-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-07-31 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Non-Small-Cell Lung
- ALK-positive Advanced NSCLC
- ALK-positive Non-small-cell Lung Cancer
- ALK-positive NSCLC
Intervention
- Drug: lorlatinib — also filed as Lorbrena
Primary outcomes
what the primary-completion date above is the date OFOverall Treatment Duration of 1L Lorlatinib
measured From treatment initiation (on or after 3 March 2021) to end of follow-up (date of death or EHR activity end date) (data cutoff 31 March 2026)
Time to Discontinuation of 1L Lorlatinib
measured From treatment initiation (on or after 3 March 2021) to end of follow-up (date of death or EHR activity end date) (data cutoff 31 March 2026)
Number of Dose Changes of 1L Lorlatinib
measured From treatment initiation (on or after 3 March 2021) to end of follow-up (date of death or EHR activity end date) (data cutoff 31 March 2026)
Rate of Discontinuation of 1L Lorlatinib
measured From treatment initiation (on or after 3 March 2021) to end of follow-up (date of death or EHR activity end date) (data cutoff 31 March 2026)
Time to next treatment (TTNT)
measured From treatment initiation (on or after 3 March 2021) to end of follow-up (date of death or EHR activity end date) (data cutoff 31 March 2026)
Clinical Characteristic of Participants: Eastern Cooperative Oncology Group (ECOG) Performance Status
measured From treatment initiation (on or after 3 March 2021) to end of follow-up (date of death or EHR activity end date) (data cutoff 31 March 2026)
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed